X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6600) 6600
Book Chapter (20) 20
Magazine Article (9) 9
Book / eBook (3) 3
Conference Proceeding (3) 3
Dissertation (1) 1
Newspaper Article (1) 1
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4447) 4447
glucagon-like peptide-1 (3374) 3374
animals (2671) 2671
diabetes mellitus, type 2 - drug therapy (2411) 2411
male (2392) 2392
endocrinology & metabolism (2297) 2297
diabetes (2054) 2054
hypoglycemic agents - therapeutic use (1972) 1972
type 2 diabetes (1912) 1912
glucagon (1686) 1686
glucose (1574) 1574
female (1557) 1557
insulin (1512) 1512
glucagon-like peptide 1 (1227) 1227
peptides (1207) 1207
middle aged (1144) 1144
glp-1 (1088) 1088
pharmacology & pharmacy (1070) 1070
liraglutide (1066) 1066
diabetes mellitus (1006) 1006
mice (1001) 1001
obesity (960) 960
blood glucose - metabolism (901) 901
glucagon-like peptide 1 - therapeutic use (889) 889
glucagon-like peptide 1 - analogs & derivatives (864) 864
rats (858) 858
glycemic control (855) 855
adult (794) 794
exenatide (761) 761
diabetes mellitus, type 2 - blood (747) 747
glucagon-like peptide 1 - metabolism (741) 741
hypoglycemic agents - pharmacology (737) 737
aged (728) 728
treatment outcome (701) 701
peptides - therapeutic use (690) 690
diabetes mellitus, type 2 - metabolism (669) 669
research (669) 669
analysis (668) 668
dipeptidyl-peptidase iv inhibitors - therapeutic use (663) 663
insulin resistance (657) 657
glucagon-like peptide-1 receptor (655) 655
insulin - metabolism (653) 653
dextrose (631) 631
care and treatment (630) 630
blood glucose - drug effects (604) 604
secretion (586) 586
rodents (584) 584
internal medicine (576) 576
hypoglycemic agents - administration & dosage (568) 568
hypoglycemic agents - adverse effects (567) 567
double-blind (564) 564
metformin (563) 563
metabolism (557) 557
physiological aspects (544) 544
hypoglycemic agents (538) 538
hyperglycemia (531) 531
venoms - therapeutic use (524) 524
health aspects (519) 519
medicine & public health (519) 519
diabetes therapy (503) 503
risk factors (503) 503
drug therapy (502) 502
insulin secretion (499) 499
beta-cell function (496) 496
abridged index medicus (481) 481
insulin - blood (481) 481
glucagon-like peptide-1 receptor - agonists (450) 450
digestive, oral, and skin physiology (439) 439
body weight (434) 434
glucagon-like peptide 1 - blood (434) 434
clinical trials (429) 429
type-2 diabetes-mellitus (426) 426
peptides - pharmacology (425) 425
incretins - therapeutic use (421) 421
glucose metabolism (420) 420
diabetes mellitus, type 2 - complications (418) 418
glucagon-like peptide 1 - pharmacology (417) 417
exendin-4 (416) 416
physiology (416) 416
endocrine system (413) 413
receptors, glucagon - agonists (403) 403
drug therapy, combination (400) 400
review (395) 395
diabetes mellitus, type 2 - physiopathology (391) 391
proteins (388) 388
insulin-secretion (387) 387
safety (383) 383
mice, inbred c57bl (366) 366
incretin (365) 365
expression (364) 364
medicine, research & experimental (357) 357
food-intake (354) 354
medicine, general & internal (350) 350
type 2 diabetes mellitus (350) 350
receptor (348) 348
glucagon-like peptide 1 - agonists (343) 343
medicine (343) 343
hormones, hormone substitutes, and hormone antagonists (338) 338
insulin-resistance (338) 338
obesity - drug therapy (338) 338
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6480) 6480
German (45) 45
Japanese (43) 43
Spanish (26) 26
French (25) 25
Chinese (15) 15
Czech (13) 13
Danish (9) 9
Italian (9) 9
Polish (7) 7
Portuguese (7) 7
Hungarian (6) 6
Russian (5) 5
Dutch (4) 4
Swedish (4) 4
Korean (2) 2
Bosnian (1) 1
Croatian (1) 1
Finnish (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9683, pp. 39 - 47
... assigned to receive additional liraglutide 1·8 mg once a day (n=233) or exenatide 10 μg twice a day (n=231) in a 26-week open-label, parallel-group, multinational... 
Internal Medicine | METFORMIN | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | HUMAN GLP-1 ANALOG | BETA-CELL MASS | TREATED PATIENTS | ACUTE-PANCREATITIS | WEIGHT | Nausea - chemically induced | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glucagon-Like Peptide 1 - agonists | Injections, Subcutaneous | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Peptides - chemistry | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glucagon-Like Peptide 1 - chemistry | Linear Models | Logistic Models | Treatment Outcome | Hypoglycemic Agents - chemistry | Blood Glucose - drug effects | Analysis of Variance | Venoms - therapeutic use | Venoms - chemistry | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Hypoglycemic agents | Dosage and administration | Drug therapy | Molecular structure | Clinical trials | Diabetes | Clinical medicine | Apoptosis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
.... DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active GLP-1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 08/2009, Volume 157, Issue 8, pp. 1340 - 1351
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone secreted by the small intestine in response to nutrient ingestion. It has wide... 
heart failure | vasodilatation | sympathetic activation | incretin | glucagon-like peptide-1 | glucagon-like peptide-1 receptor | cardiac ischaemia | diabetes | glucagon‐like peptide‐1 receptor | glucagon‐like peptide‐1 | Heart failure | Incretin | Glucagon-like peptide-1 | Cardiac ischaemia | Vasodilatation | Diabetes | Sympathetic activation | Glucagon-like peptide-1 receptor | ARTERIAL-BLOOD-PRESSURE | MYOCARDIAL GLUCOSE-UPTAKE | EXENATIDE EXENDIN-4 | LEFT-VENTRICULAR PERFORMANCE | ISCHEMIA-REPERFUSION INJURY | MESSENGER-RIBONUCLEIC-ACID | INCREASES INSULIN SENSITIVITY | 7-36 AMIDE | PHARMACOLOGY & PHARMACY | BETA-CELL | HEART-RATE | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Cardiovascular Diseases - physiopathology | Cardiovascular Diseases - metabolism | Cardiovascular Diseases - drug therapy | Humans | Receptors, Glucagon - metabolism | Blood Glucose | Glucagon-Like Peptide 1 - physiology | Diabetes Mellitus, Type 2 - metabolism | Cardiovascular Agents - therapeutic use | Cardiovascular System - physiopathology | Insulin - metabolism | Animals | Diabetes Mellitus, Type 2 - physiopathology | Cardiovascular System - metabolism | Glucagon-Like Peptide-1 Receptor | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Insulin Secretion | Incretins - physiology | Insulin - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Reviews
Journal Article